Toxoplasma gondii: effects of Artemisia annua L. on susceptibility to infection in experimental models in vitro and in vivo.
Considering that the treatment for toxoplasmosis is based on drugs that show limited efficacy due to their substantial side effects, the purpose of the present study was to evaluate the effects of Artemisia annua on in vitro and in vivo Toxoplasma gondii infection. A. annua infusion was prepared from dried herb and tested in human foreskin fibroblasts (HFF) or mice that were infected with the parasite and compared with sulfadiazine treatment. For in vitro experiments, treatment was done on parasite before HFF infection or on cells previously infected with T. gondii and the inhibitory concentration (IC(50)) values for each treatment condition were determined. Viability of HFF cells in the presence of different concentrations of A. annua infusion and sulfadiazine was above 72%, even when the highest concentrations from both treatments were tested. Also, the treatment of T. gondii tachyzoites with A. annua infusion before infection in HFF cells showed a dose-response inhibitory curve that reached up to 75% of inhibition, similarly to the results observed when parasites were treated with sulfadiazine. In vivo experiments with a cystogenic T. gondii strain demonstrated an effective control of infection using A. annua infusion. In conclusion, our results indicate that A. annua infusion is useful to control T. gondii infection, due to its low toxicity and its inhibitory action directly against the parasite, resulting in a well tolerated therapeutic tool.
de Oliveira
Taísa Carrijo
TC
Laboratory of Immunoparasitology, Institute of Biomedical Sciences, Federal University of Uberlândia, Av. Pará 1720, 38400-902 Uberlândia, MG, Brazil.
Silva
Deise A Oliveira
DA
Rostkowska
Cristina
C
Béla
Samantha Ribeiro
SR
Ferro
Eloisa A V
EA
Magalhães
Pedro Mellilo
PM
Mineo
José Roberto
JR
D000818:Animals; D031172:Artemisia annua / Q000737:chemistry*; D001681:Biological Assay; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003049:Coccidiostats / Q000494:pharmacology / Q000627:therapeutic use; D016207:Cytokines / Q000032:analysis; D005260:Female; D005347:Fibroblasts; D052816:Foreskin / Q000166:cytology; D006801:Humans; D007150:Immunohistochemistry; D017737:Macrophages, Peritoneal / Q000737:chemistry / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009573:Nitrites / Q000032:analysis; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D016133:Polymerase Chain Reaction; D016205:Sigmodontinae; D013411:Sulfadiazine / Q000494:pharmacology / Q000627:therapeutic use; D014122:Toxoplasma / Q000187:drug effects* / Q000302:isolation & purification; D014124:Toxoplasmosis, Animal / Q000188:drug therapy*
D003049:Coccidiostats; D016207:Cytokines; D009573:Nitrites; D010936:Plant Extracts; D013411:Sulfadiazine